BrainStorm touts preclinical work; Antisoma encouraged by mid-stage AML trial;

> BrainStorm Cell Therapeutics says that preclinical work on its adult stem cell therapy for spinal cord injuries has demonstrated efficacy in rats. BrainStorm release 

> Antisoma says that encouraging results from a Phase II study of a new therapy for AML has convinced researchers to increase the dosage in the next mid-stage trial. Release

> Neurobiological Technologies announced that Paul E. Freiman, president and chief executive officer (CEO), has announced his intent to retire on December 31, 2008. Release

> A federal judge is urging Eli Lilly to negotiate a worldwide settlement with Zyprexa plaintiffs, who are asking for some $7.7 billion. Zyprexa report

> Where's the growth? According to a Financial Times survey, a quarter of pharma execs agree that diversifying away from medications and stepping up sales in emerging markets are the way to go. Report

> Good news for makers of cholesterol meds: The market has just expanded. For the first time, the American Academy of Pediatrics is recommending that kids as young as 8 years old be given cholesterol drugs in hopes of preventing future heart disease. Report

> A German company is snapping up APP Pharmaceuticals in a deal worth more than $4.6 billion. Report

And Finally... A woman in southern Ontario is one of the first cases in Canada of a rare neurological syndrome in which a person starts speaking with a different accent, McMaster University researchers report in the July issue of the Canadian Journal of Neurological Sciences. Release

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.